New York-based Neurogene Inc. (Nasdaq: NGNE) announced the pricing of a USD 125 million public offering of common stock and pre-funded warrants on July 1, 2026, with proceeds directed toward the ongoing clinical development of its lead gene therapy program and pre-commercial readiness activities ahead of a potential approval in Rett syndrome.
The offering comprised 3,500,000 shares of common stock priced at USD 30.00 per share, alongside pre-funded warrants for up to 666,666 shares at USD 29.999999 per warrant — a structure typically used by investors approaching beneficial ownership thresholds. Gross proceeds are expected to total approximately USD 125 million, excluding any exercise of a 30-day overallotment option granted to underwriters covering up to 624,999 additional shares. Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital, and William Blair acted as joint bookrunning managers.
Neurogene stated that net proceeds, combined with existing cash and marketable securities, will fund continued clinical development of NGN-401, pre-commercial activities for NGN-401, and general working capital. The capital raise follows a USD 200 million PIPE financing closed in November 2024, which at the time was expected to fund operations into the second half of 2027. The current offering extends that runway and supports accelerating commercial readiness ahead of potential regulatory submissions.
NGN-401 is Neurogene's lead asset, a one-time gene therapy candidate for Rett syndrome — a rare, severe X-linked neurodevelopmental disorder affecting primarily girls. The program is currently in a Phase I/II clinical trial and has accumulated a suite of regulatory designations from the US FDA, including Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations. The European Medicines Agency has granted PRIME designation, Orphan status, and Advanced Therapy Medicinal Product classification.
The USD 125 million Neurogene capital raise is the company's third significant public or institutional financing since going public through a reverse merger with Neoleukin Therapeutics in December 2023, which was accompanied by a concurrent USD 95 million PIPE. The November 2024 PIPE raised USD 200 million from a group of specialist healthcare investors including RTW Investments, Casdin Capital, EcoR1 Capital, and Redmile Group. The current offering, priced from a shelf registration declared effective in April 2025, represents a more modest raise relative to the 2024 PIPE but is structured to support a defined near-term objective: bridging the program through key clinical readouts and into pre-commercial positioning.